Lee Hyo Jeong, Kang Hyo Jeong, Kim Kang Mo, Yu Eun Sil, Kim Ki Hun, Kim Seung-Mi, Kim Tae Won, Shim Ju Hyun, Lim Young-Suk, Lee Han Chu, Chung Young-Hwa, Lee Yung Sang
Department of Internal Medicine, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Clin Mol Hepatol. 2015 Mar;21(1):60-70. doi: 10.3350/cmh.2015.21.1.60. Epub 2015 Mar 25.
BACKGROUND/AIMS: Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study was to determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) and neighboring nonneoplastic liver tissue, and elucidate its prognostic implications.
Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboring nonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patients who underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotype expression and overall survival was evaluated (development set). This association was also validated in 73 independent samples (validation set) by Western blot analysis.
FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-year survival rate, 35.3% vs. 61.8%; P=0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgical prognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statistically significant in the validation set.
FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival.
背景/目的：成纤维细胞生长因子信号传导参与肝癌发生。本研究旨在确定成纤维细胞生长因子受体（FGFR）亚型在肝细胞癌（HCC）及邻近非肿瘤性肝组织中的表达情况，并阐明其预后意义。
对870例行肝切除的HCC患者的HCC组织及配对的邻近非肿瘤性肝组织进行FGFR1、-2、-3和-4的免疫组化染色。其中，回顾了153例接受根治性切除作为主要治疗的患者的临床资料，并评估FGFR亚型表达与总生存期的关系（开发集）。通过蛋白质印迹分析在73个独立样本（验证集）中验证了这种关联。
FGFR1、-2、-3和-4在HCC中的表达率分别为5.3%、11.1%、3.8%和52.7%。在153例患者的开发集中，HCC中FGFR2阳性与总生存期显著缩短相关（5年生存率，35.3%对61.8%；P=0.02）。在开发集中，HCC中FGFR2表达是术后预后不良的独立预测因素（风险比，2.10；P=0.02）。然而，在验证集中相应的结果无统计学意义。
HCC中FGFR2表达可能是术后生存的预后指标。
